BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Employees - 62, CEO - Kristen Fortney, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 10.18, Piotroski Score(max is 10): 3, Working Capital: $376033000, Total Assets: $397654000, Retained Earnings: $-355669000, EBIT: -89449000, Total Liabilities: $18533000, Revenue: $10316000

AryaFin Target Price - $7.15 - Current Price $ - Analyst Target Price $